GRI - GRI Bio, Inc. Common Stock

Day	1m	10m	60m	PreMarket	Market	AfterHours	Gap
1.95 0.01 (0.51%)	---	---	0.0 (0.0%)	-0.07 (-3.59%)	0.06 (3.09%)	-0.04 (-2.0%)	-0.04 (-2.0%)

GRI Bio Inc is a clinical-stage biotech company focused on discovering, developing, and commercializing therapies targeting serious diseases associated with dysregulated immune responses that to inflammatory, fibrotic, and autoimmune disorders. GRI Bio's program, GRI-0621, is a small molecule RAR-beta and gamma dual agonist that inhibits the activity of human NKT I cells, returning the immune system to homeostasis. It is also an oral formulation of tazarotene, a synthetic RAR-beta and gamma selective agonist for the topical treatment of psoriasis and acne. The company's other product candidate GRI-0803 is a novel oral agonist of type 2 Natural Killer T (type 2 NKT) cells which can be a potential treatment for autoimmune disorders.

Category: PHARMACEUTICAL PREPARATIONS

Market Period: Closed

Earnings & Ratios

Basic EPS:: -1.31
Diluted EPS:: -1.31
Basic P/E:: -1.4962
Diluted P/E:: -1.4962
RSI(14) 1m:: 0.0
VWAP:: 1.96
RVol:: 1.0558

Events

Period	Kind	Movement	Occurred At
1m	Price increase 1m	2.07 +0.03 (+1.47%)	Oct 15 10:12
1m	Price decrease 1m	2.0 -0.03 (-1.4%)	Oct 15 10:08
1m	Price increase 1m	2.07 +0.09 (+4.55%)	Oct 15 10:07
10m	Price increase 10m	2.07 +0.08 (+3.92%)	Oct 15 10:07
10m	Price decrease 10m	1.94 -0.06 (-3.02%)	Oct 15 09:43